HopeStage
Back to all studies
CompletedNCT00590577

Three paliperidone palmitate doses or placebo for schizophrenia

About this titleRead the official source — NCT00590577

Researchers compared Paliperidone palmitate 25 mg eq., Paliperidone palmitate 100 mg eq., Paliperidone palmitate 150 mg eq. and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

Medication studyAges 18+Multiple countries
The study in practice

Understand this study

What did researchers investigate?

Researchers compared Paliperidone palmitate 25 mg eq., Paliperidone palmitate 100 mg eq., Paliperidone palmitate 150 mg eq. and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Listed locations
Anaheim and 65 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMarch 2007
Recruitment status
Completed
Enrollment listed in the registry
652
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Malaysia, Romania, ...
Age range
Over 18 Years
Official registry ID
NCT00590577
Official title
Show the full official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Anaheim, United States · Cerritos, United States · Escondido, United States

64 more locations
  • Glendale, United States
  • La Palma, United States
  • Los Angeles, United States
  • National City, United States
  • San Diego, United States
  • Santa Ana, United States
  • Jacksonville, United States
  • Kissimmee, United States
  • Miami, United States
  • North Miami, United States
  • Atlanta, United States
  • Hoffman Estates, United States
  • Kingsport, United States
  • Wichita, United States
  • Lake Charles, United States
  • Shreveport, United States
  • Baltimore, United States
  • Rockville, United States
  • Cedarhurst, United States
  • New York, United States
  • Olean, United States
  • Cincinnati, United States
  • Moore, United States
  • Charleston, United States
  • Austin, United States
  • Houston, United States
  • San Antonio, United States
  • Arlington, United States
  • Richmond, United States
  • Johor Bahru, Malaysia
  • Kota Bharu, Malaysia
  • Kuala Lumpur, Malaysia
  • Perak, Malaysia
  • Brasov, Romania
  • Bucharest, Romania
  • Craiova, Romania
  • Iași, Romania
  • Oradea, Romania
  • Sibiu, Romania
  • Tg Mures, Romania
  • Kazan', Russia
  • Lipetsk, Russia
  • Moscow Russia, Russia
  • Nizny Novgorod, Russia
  • Saint Petersburg, Russia
  • Samara, Russia
  • St-Petersburg Na, Russia
  • St-Petresburg, Russia
  • Yaroslavl, Russia
  • Belgrade, Serbia
  • Kragujevac, Serbia
  • Gwangju, South Korea
  • Inchun, South Korea
  • Seoul, South Korea
  • Changhua, Taiwan
  • Hualien City, Taiwan
  • Kaohsiung City, Taiwan
  • Taipei, Taiwan
  • Dnipro, Ukraine
  • Kharkiv, Ukraine
  • Kiev, Ukraine
  • Odesa, Ukraine
  • Simferopol, Ukraine
  • Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared Paliperidone palmitate 25 mg eq., Paliperidone palmitate 100 mg eq., Paliperidone palmitate 150 mg eq. and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Paliperidone palmitate 25 mg eq., Paliperidone palmitate 150 mg eq., Placebo and Paliperidone palmitate 100 mg eq..

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies